NCT04505683已完成2 期
A Phase 2, Randomized, Double-blind, Positive-control, Multicenter, Prospective Study to Assess Efficacy and Safety of Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 112
- 试验地点
- 1
- 主要终点
- Percentage of patients with clinical cure at test-of-cure (TOC) visit
研究概览
简要总结
A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects aged 18-75 years
- •Have a diagnosis of cUTI or AP as defined below:
- •cUTI definition:
- •At least Two of the following signs and symptoms:
- •Chills, rigors, or fever; fever must be observed and documented by a health care provider (tympanic temperature ≥37.3°C)
- •Flank pain or Lower abdominal pain
- •Dysuria, urgency to void, or increased urinary frequency
- •Nausea or vomiting
- •Costovertebral angle tenderness or renal percussive pain on physical examination.
- •Blood leukocytes above upper limit of normal value
- •And at least One of the following risk factors for cUTI:
- •Implanted urinary tract instrumentation (e.g., nephrostomy tube, ureteric stents), ongoing intermittent bladder catheterization, or presence of an indwelling bladder catheter (Note: bladder catheters prior to Screening should be expected to remove during study period
- •post-void residual urine volume of ≥ 100 mL;
- •Obstructive uropathy (e.g. bladder outlet obstruction, nephrolithiasis, prostatic hyperplasia) that is expected to be removed during study drug therapy;
- •Perioperative urinary tract infection.
- •AP definition: And at least One of the following signs and symptoms:
- •Chills, rigors, or fever; fever must be observed and documented by a health care provider (tympanic temperature ≥37.3°C）；
- •Flank pain
- •Dysuria, urgency to void, or increased urinary frequency
- •Nausea or vomiting
- •Costovertebral angle tenderness or renal percussive pain on physical examination.
- •Blood leukocytes above upper limit of normal value
- •Patients or legal representatives can be able to provide informed consent
排除标准
- •Receipt of potentially effective antibiotic therapy more than 24h within 72 h prior to randomization
- •Anticipated concomitant use of other systemic antibiotic drugs during the study period
- •Anticipated continnue to preventive anti-infectious therapy after cUTI patients completed investigational drug treatment
- •Presence of any known or suspected disease or condition as following:
- •Uncomplicated urinary tract infection (uUTI)
- •Fungal Urinary tract infection
- •Perinephric or renal corticomedullary abscess
- •Polycystic kidney disease
- •Urinary tuberculosis
- •Obstructive uropathy(e.g.congenital malformation) unable to remove during treatment.
- •Ideal loop surgery or vesicoureteral reflux
- •Permannent bladder catheterization or long term indwelling nephrostomy tube
- •Previous or planned renal transplantation
- •Patients undergoing dialysis"
- •Confirmed or suspected acute or chronic bacterial prostatitis, orchitis, or epididymitis
- •Confirmed or suspected sexually transmitted disease,e.g. gonorrhea and syphilis
- •Confirmed or suspected non-renal source of infection (e.g., infective endocarditis, osteomyelitis, meningitis, pneumonia)
- •Trauma to the pelvis or urinary tract within 7days before enrollment
- •Rapid onset or life-threatening diseases, such as septic shock, respiratory failure, sepsis, etc;
- •Severe cardiovascular and cerebrovascular diseases, acute myocardial infarction, acute ischemic stroke, acute Hemorrhagic stroke or intravascular intervention within recently 3 months
- •Known or suspected central nerve system disorders, prone to epilepsy(e.g severe carebral arteriosclerosis)
- •Known history of immunodeficiency diease, e.g.AIDS or human immunodeficiency virus (HIV) infection,hematologic malignancy, bone marrow transplant, or receiving immunosuppressive therapy such as cancer chemotherapy, medications for the rejection of transplantation, and long term use of systemic corticosteroids;
- •Use of valproic acid or probenecid within 30 days before enrollment or during study period.
- •Hepatic impairment at Screening, evidenced as:
- •alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3x upper limit of normal (ULN);
- •total bilirubin >1.5x ULN;
- •alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2x upper limit of normal (ULN) and total bilirubin > ULN; Creatinine clearance (CrCl) of <60 mL/min, as estimated by the Cockcroft-Gault formula: estimated Creatinine Clearance (eC_Cr) [mL/min]=((140-Age [yrs]) × Body Weight [kg] × [0.85 if Female])/(72 × Serum Creatinine [mg⁄dL])
- •Known allergic to β-lactam drugs or in an allergic state
- •Confirmed or suspected alcohol or drug abuse history
- •Patients with other mental disorders who are unable or unwilling to cooperate.
- •Pregnant or breastfeeding women or plan to pregnant and unwilling to take contraceptive methods
- •Participants in other clinical trials within 3 months before enrollment.
- •Other situations that the investigators considers not suitable to participate in this clinical trial.
研究组 & 干预措施
test drug arm
Experimental
Benapenem for IV injection administered as a 1-gram IV infusion over 30 min once daily for 7 to 14 days.
干预措施: Benapenem (Drug)
active control arm
Active Comparator
Ertapenem for IV injection administered as a 1-gram IV infusion over 30 min once daily for 7 to 14 days.
干预措施: Ertapenem (Drug)
结局指标
主要结局
Percentage of patients with clinical cure at test-of-cure (TOC) visit
时间窗: Day 7 +/- 1 days after the end of treatment
Clinical cure is defined as complete resolution of signs,symptoms and related laboratory tests of cUTI or AP that were present at baseline and no new symptoms, such that no further antimicrobial therapy is warranted.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract InfectionsAcute PyelonephritisComplicated Urinary Tract InfectionNCT05060419Qilu Pharmaceutical Co., Ltd.150
已完成
2 期
Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTIUrinary Tract InfectionsNCT03680612Allecra45
已完成
2 期
Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract InfectionsUrinary Tract InfectionsNCT01281462Forest Laboratories217
已完成
2 期
A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid ArthritisArthritis, RheumatoidNCT00308282Eli Lilly and Company136
已完成
1 期
VPM1002BC in Recurrent Non-muscle Invasive Bladder CancerBladder CancerNCT02371447Swiss Group for Clinical Cancer Research39